Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.

Hirt C; Schuler F; Dolken G

首页> 外文期刊>Seminars in cancer biology >Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.

【24h】

Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.

机译：利妥昔单抗免疫治疗时代滤泡性淋巴瘤的最小残留病（MRD）。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The t(14;18)-translocation can be detected by PCR analysis in more than 90% of cytogenetically t(14;18)-positive follicular lymphomas (FLs), thus providing an easily accessible marker for molecular disease monitoring. Various technical aspects of the detection of residual lymphoma cells as well as the prognostic and clinical significance of the detection of minimal residual disease (MRD) after radiotherapy, chemotherapy and therapy with the monoclonal antibody rituximab are discussed. Up to now the comparability of the different studies investigating minimal residual disease in follicular lymphoma patients is hampered by the use of a variety of PCR techniques. A more standardized quantitative approach based on the real-time PCR technique will provide a powerful tool for the evaluation and optimization of therapy for each individual patient.

机译：可以通过PCR分析在90％以上的细胞遗传性t（14; 18）阳性滤泡性淋巴瘤（FL）中检测到t（14; 18）易位，从而为分子疾病监测提供了一种易于使用的标记。讨论了检测残留淋巴瘤细胞的各个技术方面，以及在放射疗法，化学疗法和单克隆抗体利妥昔单抗治疗后检测最小残留疾病（MRD）的预后和临床意义。迄今为止，使用各种PCR技术阻碍了研究滤泡性淋巴瘤患者的最小残留疾病的不同研究的可比性。基于实时PCR技术的更加标准化的定量方法将为评估和优化每个患者的治疗提供强大的工具。

著录项

来源
《Seminars in cancer biology》 |2003年第3期|共9页
作者
Hirt C; Schuler F; Dolken G;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Neoplasm; Residual; Lymphoma; Follicular; rituximab; historical period; Minimal; 肿瘤; 残余; 淋巴瘤; 滤泡型;

机译：Neoplasm;Residual;Lymphoma;Follicular;rituximab;historical period;Minimal;肿瘤;残余;淋巴瘤;滤泡型;

相似文献

外文文献
中文文献
专利

1. Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. [J] . Hirt C, Schuler F, Dolken G Seminars in cancer biology . 2003,第3期

机译：利妥昔单抗免疫治疗时代滤泡性淋巴瘤的最小残留病（MRD）。
2. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). [J] . Stark B, Avigad S, Luria D, Pediatric blood & cancer . 2009,第1期

机译：流式细胞仪（FC）和实时定量聚合酶链反应（RQ-PCR）检测到儿童期T细胞淋巴母细胞性淋巴瘤III期的骨髓最小播散性疾病（MDD）和最小残留病（MRD）。
3. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network [J] . Della Starza Irene, Cavalli Marzia, De Novi Lucia Anna, Hematological oncology . 2019,第S2期

机译：非霍奇金淋巴瘤中的最小残留疾病（MRD）：在FIL（FOLAZIONE ITALIANA LINFOMI）MRD网络中具有极低疾病的骨髓样品的逆向血管性再现性
4. ELEVATION OF MINIMAL RESIDUAL DISEASE (MRD) IN THE PERIPHERAL BLOOD PRIOR TO THE CLINICAL RELAPSE IN DOGS WITH LYMPHOMA THAT ACHIEVED COMPLETE REMISSION AFTER CHEMOTHERAPY [C] . Masahiko Sato, Junpei Yamazaki, Yuko Goto-Koshino, Annual Conference of the Veterinary Cancer Society . 2009

机译：在淋巴瘤患者临床复发之前在外周血中的最小残留疾病（MRD）升高，从而在化疗后取得完全缓解
5. Effectiveness of Novel Immunotherapy and Chemotherapy Treatments for Follicular and Diffuse Large B-Cell Lymphomas [D] . Butsenko, Dmitriy. 2017

机译：新型免疫疗法和化学疗法对滤泡性和弥漫性大B细胞淋巴瘤的疗效
6. Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era? [O] . Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi 2017

机译：在化学免疫治疗时代滤泡性淋巴瘤的最小残留疾病监测有作用吗？
7. MINIMAL RESIDUAL DISEASE (MRD) IN EARLY STAGE FOLLICULAR LYMPHOMA CAN PREDICT PROGNOSIS AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY [O] . A. Pulsoni, I. Della Starza, L.V. Cappelli, 2017

机译：早期卵泡淋巴瘤的最小残留疾病（MRD）可以预测放疗后预后和挥发生肢体治疗

Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab.

摘要

著录项

相似文献

相关主题

期刊订阅